ArticleJournal of gastroenterology2017
Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.
Article in Journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Pooled it
- Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis.Scientific reports · 2020Pooled it
- Follow-up of jaundice-free biliary atresia survivors using M2BPGi and APRI in a local hospital.World journal of pediatric surgery · 2026Article
- Biomarkers in biliary atresia - an elusive promise of predicting outcome.Pediatric research · 2025Article
- Fibrotic liver injury in biliary atresia: long-term implications.World journal of pediatric surgery · 2025Review
- Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy.Pediatric surgery international · 2024Article
- Serum biomarkers for liver fibrosis assessment.Advances in laboratory medicine · 2024Review
- Article
- Galectin-3 in biliary atresia and other pediatric cholestatic liver diseases.Hepatology research : the official journal of the Japan Society of Hepatology · 2024Article
- Progress in Biomarkers Related to Biliary Atresia.Journal of clinical and translational hepatology · 2024Review
- Diagnostic performance of Mac-2-binding protein glycosylation isomer (M2BPGi) as a liver fibrosis marker in chronic hepatitis C patients with chronic kidney disease on hemodialysis.Clinical and experimental nephrology · 2023Article
- Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease.Journal of medical ultrasonics (2001) · 2023Article
- Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy.Clinical and experimental pediatrics · 2023Article
- The role of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in the assessment of fibrosis in children with chronic hepatitis C.Scientific reports · 2022Article
- Elevation of microRNA-214 is associated with progression of liver fibrosis in patients with biliary atresia.Pediatric surgery international · 2022Article
- Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children.Frontiers in pediatrics · 2022Article
- Comparison of the diagnostic performance of magnetic resonance elastography andExperimental and therapeutic medicine · 2020Article
- Novel biomarkers for the management of chronic hepatitis B.Clinical and molecular hepatology · 2020Review
- M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.World journal of gastroenterology · 2020Article
- Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMac-2 Binding Protein Glycosylation Isomer (M2BPGi) is a novel fibrosis marker. We examined the ability of M2BPGi to predict liver fibrosis in patients with biliary atresia.
methodsSixty-four patients who underwent living donor liver transplantation (LDLT) were included [median age, 1.1 years (range 0.4-16.0), male 16 patients (25.0 %)]. We examined M2BPGi levels in serum obtained the day before LDLT, and we compared the value of the preoperative M2BPGi levels with the histological evaluation of fibrosis using the METAVIR fibrosis score. Subsequently, we assessed the ability of M2BPGi levels to predict fibrosis.
resultsThe median M2BPGi level in patients with BA was 6.02 (range, 0.36-20.0), and 0, 1, 1, 11, and 51 patients had METAVIR fibrosis scores of F0, F1, F2, F3, and F4, respectively. In patients with F4 fibrosis, the median M2BPGi level was 6.88 (quartile; 5.235, 12.10), significantly higher than that in patients with F3 fibrosis who had a median level of 2.42 (quartile; 1.93, 2.895, p < 0.01). Area under the curve analysis for the ability of M2BPGi level to predict grade fibrosis was 0.917, with a specificity and sensitivity of 0.923 and 0.941, respectively. In comparison with other fibrosis markers such as hyaluronic acid, procollagen-III-peptide, type IV collagen 7 s, and aspartate aminotransferase platelet ratio index, M2BPGi showed the strongest ability to predict grade F4 fibrosis.
conclusionM2BPGi is a novel fibrosis marker for evaluating the status of the liver in patients with BA, especially when predicting grade F4 fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.